rs5882 — CETP I405V

CETP I405V — The Longevity Lipid Variant

Cholesteryl ester transfer protein (CETP) is the molecular shuttle that moves cholesterol esters from HDL to LDL and VLDL, simultaneously transferring triglycerides in the opposite direction. This exchange is a central step in reverse cholesterol transport — the process by which excess cholesterol is harvested from peripheral tissues and returned to the liver for excretion. High CETP activity tends to lower HDL levels and shrink HDL particle size; low CETP activity allows HDL to accumulate as larger, more cholesterol-rich particles.

The I405V variant at rs5882 sits in exon 14 of the CETP gene¹¹ exon 14 of the CETP gene
located on chromosome 16q13, encoding a 476-amino-acid secreted glycoprotein. Unlike the TaqIB variant (rs708272), which is a non-functional intronic marker in linkage with the functional haplotype, I405V is a direct coding change — substituting isoleucine (Ile) for valine (Val) at mature-protein position 405 (precursor position 422). This direct amino acid substitution reduces CETP secretion from hepatocytes and lowers circulating CETP protein levels.

The Mechanism

At the molecular level, the Val allele (G on the plus strand) reduces CETP protein expression. Carriers of the Val allele have measurably lower serum CETP concentrations: in the original Barzilai cohort, VV centenarians showed CETP levels of 1.73 ± 0.11 μg/mL vs 2.12 ± 0.10 μg/mL in Ile carriers (p=0.01)²² CETP levels of 1.73 ± 0.11 μg/mL vs 2.12 ± 0.10 μg/mL in Ile carriers (p=0.01). Lower CETP activity allows HDL particles to retain their cholesteryl ester cargo longer, producing larger, more buoyant HDL2 particles and elevating total HDL-C. Studies suggest VV carriers tend to have higher HDL-C levels, with the effect more pronounced in women.

The relationship between I405V and cognitive health has a plausible mechanism: HDL particles deliver cholesterol to the brain through the blood–brain barrier, and larger, lipid-rich HDL particles may support neuronal membrane integrity and myelin maintenance. Reduced CETP activity may also lower apolipoprotein B–containing particles in cerebrospinal fluid, decreasing amyloid deposition.

The Evidence

The landmark study was Barzilai et al., JAMA 2003³³ Barzilai et al., JAMA 2003, which genotyped 213 Ashkenazi Jewish centenarians (mean age 98.2 years), 216 of their offspring, and 258 age-matched controls. Centenarians and their offspring showed 2.9- to 3.6-fold enrichment (in men) and 1.5- to 2.7-fold enrichment (in women) for the VV genotype compared to controls, alongside larger HDL and LDL particle sizes, lower hypertension prevalence, and lower rates of metabolic syndrome.

The longevity-cognition link was formalized in Barzilai et al., Neurology 2006 ⁴⁴ Barzilai et al., Neurology 2006 : among cognitively intact centenarians (MMSE >25), 29% were VV vs only 14% of those with MMSE ≤25 (p=0.02). In a younger cohort (Einstein Aging Study), VV subjects showed a fivefold increase compared to expected frequency. The most quantitatively precise evidence comes from Sanders et al. 2010⁵⁵ Sanders et al. 2010: following 523 older adults for a mean 4.3 years, VV homozygotes showed significantly slower memory decline (p=0.03) and dramatically lower dementia risk (HR 0.28, 95% CI 0.10–0.85, p=0.02) and Alzheimer's disease risk (HR 0.31, 95% CI 0.10–0.95, p=0.04). The large Cache County Study⁶⁶ Cache County Study, with 4,486 subjects followed over 12 years, found each additional Val allele associated with 0.6-point/year slower cognitive decline (p=0.011).

Importantly, this picture is not universal. Yu et al. 2012⁷⁷ Yu et al. 2012 found the opposite in 1,384 European-ancestry participants: VV genotype was associated with faster cognitive decline and higher AD risk (HR 1.63). A Chinese case-control meta-analysis ⁸⁸ Chinese case-control meta-analysis across 8 studies found the V allele was protective in Ashkenazi Jews (OR 1.46) but a risk allele in East Asian populations (OR 0.67). The APOE interaction⁹⁹ APOE interaction may partly explain this: in APOE ε4 carriers, the V allele associates with preserved cortical thickness; in non-carriers, the I allele is protective. The cardiovascular evidence is similarly mixed — the Val allele reliably raises HDL but does not consistently reduce cardiovascular events, mirroring failures of CETP inhibitor drugs in clinical trials.

Practical Actions

For GG (VV) carriers, the primary implication is the established HDL-raising effect: monitor HDL particle size (not just HDL-C) to confirm the phenotypic benefit, and support it through dietary choices known to synergize with endogenous CETP inhibition. Plant sterols (2 g/day) significantly lower triglycerides in GG individuals specifically, with no effect in other genotypes — making this a targeted dietary intervention. Niacin also raises HDL and reduces CETP activity, potentially amplifying the GG genotype's effect.

For AA (II) carriers, HDL-C and HDL particle size are worth monitoring, as higher CETP activity tends to produce smaller, denser HDL particles. Dietary strategies that modulate CETP activity — plant sterols, omega-3 fatty acids, moderate alcohol avoidance — may partially compensate for the higher CETP burden.

Interactions

The most clinically relevant interaction is with APOE genotype. The APOE ε4 allele independently raises Alzheimer's disease risk and alters lipid metabolism. In APOE ε4 carriers, the CETP Val allele appears to protect against medial temporal lobe atrophy; in non-carriers, the Ile allele is paradoxically protective. This complex interaction suggests that CETP I405V genotype should be interpreted alongside APOE status, and the net effect on neurological risk depends substantially on APOE background.

The rs708272 TaqIB variant (in the heart-inflammation category) is in strong linkage disequilibrium with rs5882 in European populations, and these two markers tag the same functional haplotype. Both should not be used simultaneously to predict CETP activity — I405V (rs5882) is the direct functional variant, while TaqIB is a proxy.